NASDAQ:NBIX - Neurocrine Biosciences Stock Price, Price Target & More

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its quarterly earnings results on Monday, April, 30th. The company reported ($0.47) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.29) by $0.18. The business had revenue of $71.08 million for the quarter, compared to analysts' expectations of $65.17 million. Neurocrine Biosciences had a negative return on equity of 29.67% and a negative net margin of 45.56%. During the same quarter in the previous year, the firm posted ($0.90) EPS. View Neurocrine Biosciences' Earnings History.

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Neurocrine Biosciences.

13 analysts have issued 12-month price targets for Neurocrine Biosciences' stock. Their predictions range from $79.00 to $120.00. On average, they expect Neurocrine Biosciences' stock price to reach $102.7692 in the next twelve months. View Analyst Ratings for Neurocrine Biosciences.

Some companies that are related to Neurocrine Biosciences include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Crispr Therapeutics (CRSP), argenx (ARGX), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Atara Biotherapeutics (ATRA) and Repligen (RGEN).

Media coverage about NBIX stock has been trending somewhat positive on Wednesday, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Neurocrine Biosciences earned a media sentiment score of 0.12 on Accern's scale. They also gave news stories about the company an impact score of 45.99 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Neurocrine Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.46%), BB Biotech AG (3.79%), Franklin Resources Inc. (2.62%), Artisan Partners Limited Partnership (2.19%), Wells Fargo & Company MN (1.06%) and OppenheimerFunds Inc. (0.93%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Stephen A Sherwin, Timothy P Coughlin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.

NBIX stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Millennium Management LLC, Neuberger Berman Group LLC, Dupont Capital Management Corp, DekaBank Deutsche Girozentrale, A.R.T. Advisors LLC, BB Biotech AG and Candriam Luxembourg S.C.A.. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Stephen A Sherwin and William H Rastetter. View Insider Buying and Selling for Neurocrine Biosciences.

NBIX stock was bought by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Artisan Partners Limited Partnership, Victory Capital Management Inc., BlackRock Inc., Rock Springs Capital Management LP, Point72 Asset Management L.P., Amundi Pioneer Asset Management Inc. and Columbus Circle Investors. View Insider Buying and Selling for Neurocrine Biosciences.

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NBIX stock can currently be purchased for approximately $102.72.

Neurocrine Biosciences has a market capitalization of $9.20 billion and generates $161.63 million in revenue each year. The company earns $-142,540,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Neurocrine Biosciences employs 400 workers across the globe.

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]